Can Fite Biopharma Ltd (NYSEAMERICAN:CANF) saw a large increase in short interest in January. As of January 31st, there was short interest totalling 691,907 shares, an increase of 218.7% from the January 12th total of 217,077 shares. Based on an average daily volume of 408,500 shares, the short-interest ratio is presently 1.7 days.
Several brokerages have weighed in on CANF. Maxim Group set a $7.00 price objective on Can Fite Biopharma and gave the company a “buy” rating in a research note on Monday, December 18th. HC Wainwright set a $6.00 target price on Can Fite Biopharma and gave the company a “buy” rating in a research report on Tuesday, October 31st.
An institutional investor recently bought a new position in Can Fite Biopharma stock. Meitav Dash Investments Ltd. acquired a new position in Can Fite Biopharma Ltd (NYSEAMERICAN:CANF) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 155,000 shares of the biotechnology company’s stock, valued at approximately $240,000. Meitav Dash Investments Ltd. owned about 0.93% of Can Fite Biopharma as of its most recent filing with the Securities and Exchange Commission. 5.12% of the stock is currently owned by institutional investors and hedge funds.
Shares of Can Fite Biopharma (NYSEAMERICAN:CANF) traded down $0.02 during trading on Friday, hitting $2.03. The stock had a trading volume of 29,431 shares, compared to its average volume of 260,919. Can Fite Biopharma has a 1 year low of $1.24 and a 1 year high of $2.75. The stock has a market cap of $34.29, a price-to-earnings ratio of 6.24 and a beta of 1.79.
Can Fite Biopharma (NYSEAMERICAN:CANF) last announced its quarterly earnings data on Monday, November 27th. The biotechnology company reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.13) by $0.09. Can Fite Biopharma had a negative return on equity of 57.94% and a negative net margin of 2,453.03%.
TRADEMARK VIOLATION NOTICE: “Short Interest in Can Fite Biopharma Ltd (CANF) Grows By 218.7%” was first posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this report on another publication, it was stolen and reposted in violation of international trademark & copyright legislation. The correct version of this report can be viewed at https://ledgergazette.com/2018/02/17/can-fite-biopharma-ltd-canf-sees-large-growth-in-short-interest.html.
Can Fite Biopharma Company Profile
Can Fite Biofarma Ltd is an Israel-based biopharmaceutical company. The Company develops new treatments for autoimmune diseases and cancer. The Company’s drugs are CF101 for Psoriasis treatment, RA treatment, for the treatment of Keratoconjunctictivitis Sicca, for the treatment of Glaucoma, among others; and CF102 for the treatment of liver diseases.
Receive News & Ratings for Can Fite Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Can Fite Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.